| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_677137274f8c3c0f60659d437587d931
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd1fcf383108255c0c37f8a99d0df33f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec52284c90d60a414a4b4eadc092dcc8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f1dac593e362a19c7512ef3fed112fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5700b10737a00a300a2c74f55bb6078 |
| publicationDate |
2006-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006041890-A2 |
| titleOfInvention |
Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
| abstract |
The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357483-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335395-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10098905-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9186420-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779641-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11298342-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11547717-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10039822-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717569-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11235057-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668053-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633422-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10071114-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10046064-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9993548-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426451-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9987354-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009075815-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10434088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10420835-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10004802-B2 |
| priorityDate |
2004-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |